COVID-19 and systemic sclerosis: clinicopathological implications from Italian nationwide survey study

Aktualisierte Handlungsempfehlungen der Deutschen Gesellschaft für Rheumatologie für die Betreuung von Patienten mit entzündlich-rheumatischen Erkrankungen im Rahmen der SARS-CoV‑2/COVID‑19-Pandemie einschließlich Empfehlungen zur COVID‑19-Impfung

“…im Vergleich zu einer "gematchten" Population ohne ERE bei bestimmten Patientenpopulationen, z. B. bei Patienten mit systemischer Sklerose, berichten [20][21][22], weisen andere auf ein vergleichbares Risiko zur Normalbevölkerung hin [23][24][25].…”

Effect of the COVID-19 pandemic on patients with systemic rheumatic diseases

“…5 Notably, differences in prevalence have been reported according to types of rheumatic disease, with patients with connective tissue diseases showing a higher prevalence of COVID-19 than patients with chronic arthritis. 6 Moreover, COVID-19 is more prevalent in patients with pre-existing interstitial lung disease than in those without, 6 and interstitial lung disease is associated with a more severe COVID-19 pneumonia, and a worse prognosis. Thus, the risks of COVID-19 in people with rheumatic diseases are complex and varied, as are the challenges faced in deciding how to reduce the risk of infection by SARS-CoV-2.…”

“…Notably, the risk of developing severe COVID-19 is particularly high in patients with rheumatic disease who have pre-existing interstitial lung disease and in the subgroup of those with connective tissue disease. 6 People with rheumatic diseases continued therapy and followed public health advice to mitigate the risks of COVID-19. Substantial employment status changes occurred, with potential implications for health-care access, medication affordability, mental health, and rheumatic disease activity.…”

Updated recommendations of the German Society for Rheumatology for the care of patients with inflammatory rheumatic diseases in the context of the SARS-CoV-2/COVID-19 pandemic, including recommendations for COVID-19 vaccination

“…While some studies report an increased risk of COVID-19 compared to the normal population or compared to a “matched” population without IRD in certain patient populations, e.g. in patients with systemic sclerosis [ 20 – 22 ], others indicate a comparable risk to the normal population [ 23 – 25 ].…”